Introduction: The pursuit for higher oral bioavailability of macromolecules to make commercial treatments that are feasible and scalable for patients has been the holy grail for research groups and companies alike throughout the last century. McMurray 1992 suggests that including a vasodilator in an oral pharmaceutical composition can improve the onset of oral absorption of small molecules1. The current study is exploring whether this approach can be utilized to improve the exposure of acylated peptides, without undesired systemic effects, in combination with SNAC.
Learning Objectives:
Describe how bioavailability of acylated peptides can be improved preclinically
Describe that translation from preclinical to clinical research can be complicated
